Gut microbiota modulates hyodeoxycholic acid to inhibit leukemia development
Clinical Science · 2026
DOI: 10.1042/cs20261592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2026. Verfasst von Wanying Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Gastrointestinal Microbiome. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
To explore the role of gut microbiota and bile acid (BA) metabolism in acute myeloid leukemia (AML), we analyzed samples from 29 patients via 16S rDNA sequencing and LC-QTOF-MS, and performed functional studies on Enterococcus faecalis and hyodeoxycholic acid (HDCA). Results revealed a dynamic shift in gut microbiota diversity during treatment, which recovered after therapy. Notably, the abundance of Enterococcus at baseline was significantly correlated with clinical response after treatment. Furthermore, fecal microbiota transplantation (FMT) using E. faecalis reduced in vivo leukemia burden and increased levels of BAs such as HDCA. In vitro analyses demonstrated that HDCA suppresses AML cell growth and promotes apoptosis through inhibition of NF-κB, mitochondrial dysfunction, and cell cycle arrest. These findings were corroborated in a mouse model, where HDCA delayed leukemia progression and improved survival. Clinically, higher baseline serum HDCA correlated with greater gut microbiota α diversity and was associated with complete remission. In summary, Enterococcus levels and baseline HDCA are linked to AML treatment outcomes. E. faecalis FMT ameliorates AML with concurrent rises in fecal HDCA, while HDCA exerts anti-leukemic effects by targeting NF-κB, disrupting mitochondrial integrity, arresting the cell cycle, and triggering apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China.
- Fujian Medical University Union Hospital, Fuzhou, China.
- The Third People's Hospital of Hubei Province, Affiliated Hospital of Jianghan University, Wuhan, China.
- Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
- Institute of Precision Medicine, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China.
- Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Jianda Hu
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Liu, W., Yang, J., Chen, Y., Chen, S., Li, J., Yang, T., Zhang, G., & Hu, J. (2026). Gut microbiota modulates hyodeoxycholic acid to inhibit leukemia development. Clinical Science. https://doi.org/10.1042/cs20261592
Vancouver
Liu W, Yang J, Chen Y, Chen S, Li J, Yang T, et al. Gut microbiota modulates hyodeoxycholic acid to inhibit leukemia development. Clinical Science. 2026. doi:10.1042/cs20261592
BibTeX
@article{Liu2026,
author = {Liu, Wanying and Yang, Jiajie and Chen, Yanxin and Chen, Shaozhen and Li, Jiazheng and Yang, Ting and Zhang, Guanbin and Hu, Jianda},
title = {Gut microbiota modulates hyodeoxycholic acid to inhibit leukemia development},
journal = {Clinical Science},
year = {2026},
doi = {10.1042/cs20261592}
}
EUVIMED